PDCD1 and neoplasm: A lack of T cells in the tumor may lead to resistance to immunotherapy, and the immunosuppressive tumor microenvironment (TME) prevents the immune efficacy of programmed cell death protein 1 (PD-1) checkpoint inhibitors (6).